Nisa Investment Advisors LLC Buys 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Nisa Investment Advisors LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report) by 23.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,317 shares of the biotechnology company’s stock after buying an additional 247 shares during the period. Nisa Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $160,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank boosted its stake in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the third quarter worth $59,000. Institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the subject of several research analyst reports. Robert W. Baird reduced their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Finally, Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Read Our Latest Research Report on SRPT

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $114.45 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The firm has a fifty day moving average price of $122.81 and a 200-day moving average price of $127.50. The stock has a market cap of $10.93 billion, a PE ratio of 91.56 and a beta of 0.77.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Profile

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Further Reading

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.